Zeltiq Aesthetics Inc  

(Public, NASDAQ:ZLTQ)   Watch this stock  
Find more results for Zeltiq Aesthetics Inc�
16.79
+0.34 (2.07%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.47 - 16.82
52 week 5.86 - 24.79
Open 16.59
Vol / Avg. 474,680.00/437,908.00
Mkt cap 627.98M
P/E     -
Div/yield     -
EPS -0.52
Shares 37.40M
Beta     -
Inst. own 94%
Jul 29, 2014
Q2 2014 ZELTIQ Aesthetics Inc Earnings Call - 4:30PM EDT - Add to calendar
Jul 29, 2014
Q2 2014 ZELTIQ Aesthetics Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 11, 2014
ZELTIQ Aesthetics Inc at Goldman Sachs Healthcare Conference
Jun 10, 2014
ZELTIQ Aesthetics Inc at William Blair & Company LLC Growth Stock Conference
Jun 2, 2014
ZELTIQ Aesthetics Inc at Jefferies Global Healthcare Conference (One-on-One Meeting)
May 30, 2014
ZELTIQ Aesthetics Inc Annual Shareholder Meeting
Apr 29, 2014
Q1 2014 ZELTIQ Aesthetics Inc Earnings Conference Call
Apr 29, 2014
Q1 2014 ZELTIQ Aesthetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -23.69% -17.29%
Operating margin -23.28% -17.33%
EBITD margin - -15.78%
Return on average assets -34.71% -21.65%
Return on average equity -49.86% -28.57%
Employees 297 -
CDP Score - -

Address

Suite 100, 4698 Willow Road
PLEASANTON, CA 94588
United States - Map
+1-925-4742500 (Phone)
+1-925-4742599 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zeltiq Aesthetics, Inc. operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. It develops Cryolipolysis, a technology that enables the reduction of fat tissue near nerves, muscle, and bones. The Company develops a non-invasive technology for aesthetic applications and plastic surgery. Its product is used as a skin cooling device to minimize pain and thermal injury during laser and dermatological treatments.

Officers and directors

Mark J. Foley President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Patrick Williams Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Sergio Garcia-Rodriguez Senior Vice President, General Counsel and Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Keith Sullivan Senior Vice President of Worldwide Sales
Age: 55
Bio & Compensation  - Reuters
Len DeBenedictis Chief Technology Officer
Age: 72
Bio & Compensation  - Reuters
Carl Lamm Vice President of Operations
Age: 51
Bio & Compensation  - Reuters
Mary M. Fisher Director
Age: 52
Bio & Compensation  - Reuters
D. Keith Grossman Director
Age: 54
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 55
Bio & Compensation  - Reuters
Kevin C. O'Boyle CPA Independent Director
Age: 58
Bio & Compensation  - Reuters